Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced the completion of dosing in their second cohort of its Phase 1/2… Read More »Ocugen Inc completes dosing of a Phase 1/2 study for a modifier gene therapy to treat Stargardt disease.
A study from Johnson & Johnson Innovative Medicine, New Jersey, United States, report that patients with delayed genetic testing may incur significantly higher healthcare costs… Read More »Johnson & Johnson study reports the economic value of early genetic testing in inherited retinal dystrophies diagnosis.
A US company, LumiThera Inc., based in Seattle, WA, has announced a multi-centre clinical registry study to enroll up to 1,000 AMD patients with their… Read More »LumiThera Inc. have announced a multi-centre registry (“EUROLIGHT”) for their photo-biomodulation (PBM) treatment of dry AMD across up to 20 European centres.
A report in Retina Today, entitled, “A new perspective on the retina wage gap”, by Aidan Gilson, BS and Ron Adelman, MD, MPH, MBA, showed… Read More »A report from authors at the Yale School of Medicine suggest that disparities persist between female and male retina specialists.
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced results from a new meta-analyses proposing that those treated with LUMEVOQ… Read More »GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced positive clinical study update of a Phase 1/2 study of “OCU400”, a… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).
Adverum Biotechnologies (NASDAQ: ADVM) has announced to sell approximately 106.25 million shares of its common stock at a price per share of $1.20 to institutional… Read More »Advernum Biotechnologies (NASDAQ: ADVM) has raised $127.5 million to progress gene therapy pipeline.
The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8mg, 114.3 mg/ml solution for injection) for… Read More »The European Commission has approved aflibercept (8mg) for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
According to the US District Court for the Northern District of West Virginia, US, a Regeneron patent (#11,084,865) has been successfully defended for certain ophthalmic… Read More »Regeneron wins a patent ruling to extend Eylea protection but two other patents were deemed invalid.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved “Vabysmo”… Read More »Genentech (Roche Group) has reported approval from FDA for faricimab-svoa for the treatment of macular edema following Retinal Vein Occlusion (RVO).
